Anti-Rheumatic Rx
Check out our many podcasts from the ACR 2020 meeting - listen in for faculty reports and overviews. You can also find the RheumNow podcast on Apple Podcast, Apple Car Play, Android Auto or where ever you prefer to listen.
Listen here:
Day 5.1
Check out our many podcasts from the ACR 2020 meeting - listen in for faculty reports and overviews. You can also find the RheumNow podcast on Apple Podcast, Apple Car Play, Android Auto or where ever you prefer to listen.
Listen here:
Day 4.6
Check out our many podcasts from the ACR 2020 meeting - listen in for faculty reports and overviews. You can also find the RheumNow podcast on Apple Podcast, Apple Car Play, Android Auto or where ever you prefer to listen.
Listen here:
Day 4.4
The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020. Watch now!
Rheumatology Round-Up with Drs. Kavanaugh & Cush
The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020.
New ACR RA Guidelines and Practice Changing Abstracts: RA Panel
Dr. Jonathan Kay leads an international panel on the new ACR RA guidelines and other practice-changing abstracts presented at the 2020 ACR annual meeting. Panelists include Dr.Kathryn Dao, Dr. Eric Dein, Dr. Meral El Ramahi, Dr. Richard Conway and Dr. Sheila Reyes.
COVID: DMARDs, Steroids, a Vaccine - and how long will this continue? Dr. Winthrop Discusses
Dr. Kevin Winthrop reviews all things COVID-related including abstract L01, steroids and DMARDs, vaccination status - and how long this pandemic will last.
Adverse Events in Low-Dose Methotexate: Dr. Eric Dein
Dr. Eric Dein reviews abstract #2001 presented at the 2020 ACR annual meeting.
Meral K. El Ramahi, MD MeralElRamahiMD
4 years 7 months ago
Inadequate response to MTX, what next?
“Are you forward thinking or are you stuck in the past? Conceptually it is just amazing that you can take a PO tablet as potent as a TNF or IL6 blocker... & the side effects are not so appalling.”—Dr. GreggSilverman. @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD
4 years 7 months ago
When do you think we are going to get a DMARD for OA? 50% or more over age 60 will have osteoarthritis, yet we are yet to discover a promising disease modifying therapy. #ACR20 @RheumNow @ElaineHusniMD
Meral K. El Ramahi, MD MeralElRamahiMD
4 years 7 months ago
Summary of #ACR20 part A:
- HCQ is not a problem in rheumatic dz pts in terms of causing QTc prolongation
- Anti-phospholipid ab are found in a majority of hospitalized COVID19 pts — the most prevalent of which were anti-PST abs that are not in the of criteria for APS
@rheumnow
The final day (day 4) of the ACR 2020 meeting saw a flurry of late-breaking abstracts and other novel studies that excited our faculty. Below are some of their choices for #ACRbest.
Eric Dein ejdein1
4 years 7 months ago
Abst#2001: Heme changes on MTX? CIRT trial (non-rheumatic pts): Low-dose MTX (15-20mg/w): 2 line cytopenia uncommon (4%), pancytopenia rare (0.5%), Hb decrease 0.4 g/dL but WBC, plt unchanged. Reassuring large pop study shows tolerance of MTX #ACR20 @Rheumnow
Eric Dein ejdein1
4 years 7 months ago
Abst#2000. PRIME team Medicare database study pts with new RA started on MTX higher VTE risk than HCQ (HR 2.3). Unable to assess disease activity because claims database, but would imagine MTX grp more severe, driving increased VTE risk @RheumNow #ACR20 https://t.co/Z14xFTVXTp
Robert B Chao, MD doctorRBC
4 years 7 months ago
COX2 inhibitors associated with inhibition of radiographic spinal progression in AxSpA pts compared to non-selective NSAIDs.
⬇️radiographic spinal progression over 2 yrs
⬇️mSASSS progression
@RheumNow #ACR20 Abs#2030 https://t.co/p1CeNBm3ma
Poster Hall